ERBB2 and breast carcinoma: The evolution from a dichotomous (HER2‐positive and HER2‐negative) to a trichotomous (HER2‐positive, HER2‐low, and HER2‐0) classification of HER2 status has undoubtedly facilitated personalized breast cancer treatment.